Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Keros Therapeutics ( (KROS) ) has provided an update.
On May 12, 2025, Keros Therapeutics announced that its Chair and CEO, Jasbir S. Seehra, will participate in a fireside chat at the Bank of America 2025 Global Healthcare Conference on May 13, 2025. This participation highlights Keros’ engagement with the healthcare investment community and may enhance its visibility and influence within the industry.
The most recent analyst rating on (KROS) stock is a Buy with a $100.00 price target. To see the full list of analyst forecasts on Keros Therapeutics stock, see the KROS Stock Forecast page.
Spark’s Take on KROS Stock
According to Spark, TipRanks’ AI Analyst, KROS is a Neutral.
Keros Therapeutics is a high-risk, high-reward biotech company. The strong balance sheet and significant revenue growth are positive, but ongoing unprofitability and reliance on external financing are key risks. Technical indicators show moderate short-term momentum, but valuation metrics are challenging due to the negative P/E ratio. The overall score reflects these mixed factors, indicating potential for growth tempered by financial and operational challenges.
To see Spark’s full report on KROS stock, click here.
More about Keros Therapeutics
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-ß) family of proteins. The company is a leader in understanding the role of TGF-ß proteins in regulating the growth, repair, and maintenance of various tissues. Keros is developing several product candidates, including cibotercept for pulmonary arterial hypertension, KER-065 for neuromuscular diseases, and elritercept for treating cytopenias in myelodysplastic syndrome and myelofibrosis.
Average Trading Volume: 1,074,771
Technical Sentiment Signal: Sell
Current Market Cap: $554.4M
For a thorough assessment of KROS stock, go to TipRanks’ Stock Analysis page.